Last reviewed · How we verify
Triptorelin acetate （3.75mg）
Triptorelin acetate （3.75mg） is a Small molecule drug developed by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University. It is currently FDA-approved.
Triptorelin acetate (3.75mg) is used in fertility-sparing therapy for conditions such as endometriosis and endometrial neoplasms. It is administered via a 1-month depot injection formulation.
At a glance
| Generic name | Triptorelin acetate （3.75mg） |
|---|---|
| Sponsor | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- FET in Adenomyosis (NA)
- Neoadjuvant Chemotherapy With or Without GnRH Agonist for Premenopausal Triple-negative Early Breast Cancer Patients (PHASE2)
- Efficacy, Metabolism and BMD of the 3-month TP Compared to the 1-month TP in ICPP (PHASE4)
- Fertility-sparing Therapy for Patients With Stage IA Endometrial Cancer (NA)
- Study to Compare the Oestradiol Suppression, Clinical Efficacy and Safety of Two Formulations of Triptorelin (Triptorelin Pamoate PR 3-month and Triptorelin Acetate PR 1-month) in Chinese Subjects With Endometriosis (PHASE3)
- The Effectiveness and Safety of the Prolonged Down-regulation Protocol for Controlled Ovarian Hyperstimulation (PHASE4)
- A Study to Describe the Efficacy of Diphereline Following Conservative Surgery in Deep Infiltrating Endometriosis (DIE) Patients Over a Period of 24 Months
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Triptorelin acetate （3.75mg） CI brief — competitive landscape report
- Triptorelin acetate （3.75mg） updates RSS · CI watch RSS
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University portfolio CI
Frequently asked questions about Triptorelin acetate （3.75mg）
What is Triptorelin acetate （3.75mg）?
Who makes Triptorelin acetate （3.75mg）?
What development phase is Triptorelin acetate （3.75mg） in?
Related
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing